4th SPRING SENIOR SUMMIT · strategic partnering in coordination with academia to bring new...
Transcript of 4th SPRING SENIOR SUMMIT · strategic partnering in coordination with academia to bring new...
4th Annual Meeting
SPRING SENIOR SUMMIT
Saturday, April 14, 2018
8:00 am to 3:30 pm
Workforce Alliance
Wichita, KS
Friday, April 13th 6:30pm Happy Hour
Scotch & Sirloin, 5325 E. Kellogg Drive, Wichita, Kansas 67218
7:00pm Dinner Scotch & Sirloin, 5325 E. Kellogg Drive, Wichita, Kansas 67218 Hosted by Sunovion
Saturday, April 14th 7:30am-8:00am Registration
7:45am-9:20am Continental Breakfast
8:00am-8:10am Opening Statements and Introductions
8:10am-9:10am
Addiction Curtis Prichard, PharmD
9:10am-9:20am Break
9:20am-10:20am Meet the CYP’s: Review of Cytochrome P450 Janell Mayer, PharmD, BCPS, BCGP
10:20am-10:30am Break
10:30am-12:00pm Antibiotic Stewardship John W. Millard, PharmD, BCPS, BCGP
12:00pm-1:30pm Lunch and Product Theatre
1:30pm-3:00pm Geri-Jeopardy: An Active Learning Challenge of Geriatric Pharmacy Knowledge Jennifer Warren, PharmD, BCGP, FASCP & Jenny Cole, PharmD, BCPS, BCPP, BCGP
3:00pm-3:30pm Closing Remarks and Awards
Special thanks to our 2017-2018 Board Members and Committee Volunteers 2017-2018 Kansas ASCP Board Members: Lindsey Votaw PharmD, BCPS, BCGP Immediate Past-President, Board Member Jennifer Warren, PharmD, BCGP, FASCP President, Board Member Bradley J. Newell, PharmD, BCACP, BCGP President-Elect, Board Member Chair of Student Engagement Committee Chair of Meetings Committee John W. Millard, PharmD, BCPS, BCGP Secretary/Treasurer, Board Member Chair of Education Committee Mike Coast, RPh, BCGP Board Member Co-Chair of Membership Committee
Kendra Strum, PharmD, BCGP Board Member Co-Chair of Membership Committee Marwa Buser, PharmD, BCPS, BCGP Board Member Chair of Legal Committee Whitney Zentgrapf, PharmD, BCGP Board Member Chair of Community Outreach Brandon Blehm Non-Voting Board Member KU-ASCP Student Liaison
2017-2018 Kansas ASCP Committee Members: Meetings Committee: Chair: Bradley Newell Jennifer Warren John Millard Jenny Cole Lindsey Votaw Brandon Blehm Membership Committee: Co-Chair: Mike Coast Co-Chair: Kendra Strum Community Outreach Committee: Chair: Whitney Zentgrapf Marwa Buser
Education Committee Chair: John Millard Jennifer Warren Janell Mayer Student Engagement Committee Chair: Bradley J. Newell Marwa Buser Brandon Blehm Legal Committee Chair: Marwa Buser LaTonyua Rice
Kansas Chapter
Speaker Biographies: Dr. Curtis L Prichard, Pharm.D. – Opioid Addiction, The Disease Process, Neurobiological Changes and Treatment Options. Dr. Prichard earned his Doctor of Pharmacy degree from Creighton University School of Pharmacy and Health Professions. He is currently employed by Indivior Pharma PLC as a Regional Medical Scientist. He is trained in opioid addiction and utilizes his expertise as an educator for key opinion leaders in the field of addiction. Dr. Prichard directly educates physician providers on the pathophysiology of addiction and treatment options. Dr. Prichard also identifies novel molecules in early stages of development for strategic partnering in coordination with academia to bring new addiction treatment options to market. Dr. Prichard actively consults with Indivior’s Research and Development team on feasibility, study design, and viability of these new treatment modalities. Dr. Prichard performed similar roles over the past 20 years during his time in the pharmaceutical industry. Other companies include Bristol Meyer Squibb’s cardiovascular division (New Oral Anticoagulants), and Teva Pharmaceuticals Respiratory & Immunology division focusing in airway disease. Dr. John W. Millard, Pharm.D., BCPS, BCGP – Antimicrobial Stewardship – A Opportunity for All Dr. Millard earned his Doctor of Pharmacy degree from Creighton University School of Pharmacy and Health Professions. Shortly after graduation Dr. Millard co-founded Recalcitrant Sciences LLC a biotechnology company focusing on meningitis and neurological diagnostic modalities. Dr. Millard is employed by the Robert J. Dole VA Medical Center as a Clinical Pharmacy Specialist with focus practice areas in Internal Medicine, Critical Care, and Infectious Disease. Dr. Millard has a collaboration agreement with an infectious disease physician including a very broad scope of practice with prescription authority. During his tenure Dr. Millard has obtained several advanced Antimicrobial Stewardship Certifications. Including Making a Difference in Infectious Diseases as well as from the Society of Infectious Diseases Pharmacists. Dr. Millard is associated with several infectious disease case reports and poster publications most recently at the American College of Physicians via KU School of Medicine. Dr. Millard serves as a Kansas University Medical Center community faculty member as a pharmacotherapy content expert for their Quality Grand Rounds. Dr. Millard created and acts as the Robert J. Dole VA Medical Center Program Manager for the Clinical Pharmacy In-Service Educational Series. Teaching responsibilities include training KU medical residents on Antimicrobial Stewardship, annual Medical Grand Rounds, and monthly Quality Grand Rounds. He also serves as a preceptor for APPE students in internal medicine and infectious diseases.
Dr. Janell Mayer, Pharm.D. BCGP, BCPS – Meet the Cyps
Dr. Janell Mayer, Pharm.D., BCGP, BCPS is a clinical educator at Wichita State University in the School of Nursing and has an appointment at the University of Kansas as an Adjunct Clinical Assistant Professor in the Department of Pharmacy Practice. She received her BS in Pharmacy from Southwestern Oklahoma State University and her Pharm.D. from the University of Kansas. She has 12 years of geriatric practice in long term care and is a Board Certified Geriatric Pharmacist. She also is a Board Certified Pharmacotherapy Specialist. Dr. Mayer served as President of the Kansas Chapter of the American Society of Consultant Pharmacists.
Dr. Jenny Cole, Pharm.D., BCPS, BCGP, BCPP – Geri-Jeopardy Dr. Jenny Cole is currently a pharmacist at Wesley Rehabilitation Hospital in Wichita, KS. She graduated from the University of Kansas in 2000. Before moving back to Wichita in 2014, Jenny worked for Stormont Vail Hospital where she was the Senior Diagnostic Unit pharmacist. She then went on to manage Genoa Psychiatric Pharmacy, where she was instrumental in starting an indigent fund to help people obtain their medications when they could not afford to pay for them on their own. Jenny is the owner of JLC Pharmacy Services, which focuses on helping community pharmacies manage their MTMs and immunization services. At the 2017 annual KPHA convention she was awarded the MTM Champion Award in 2017 from Sunflower, for having completed the most MTMs in the state of KS. Jenny is a past board member of the KS chapter of ASCP and is board certified in pharmacotherapy, geriatrics, and psychiatric pharmacy.
Dr. Jennifer Warren, PharmD, BCGP, FASCP – Geri-Jeopardy: An Active Learning Challenge of Geriatric Pharmacy Knowledge Dr. Jennifer Warren is the Director of Pharmacy at Wesley Rehabilitation Hospital in Wichita, Kansas. She received her Doctorate of Pharmacy from the University of Colorado Denver Skaggs School of Pharmacy and her Bachelor of Science in Pharmacy from Southwestern Oklahoma State University. She is a Board Certified Geriatric Pharmacist and became a Certified Pain Educator in 2012. Jennifer is the current president of the Kansas chapter of the American Society of Consultant Pharmacists (ASCP) and is also a Fellow of ASCP. She completed two ASCP Foundation Traineeships, one in Parkinson’s Disease and the other in pain management. She also enjoys serving as a preceptor for pharmacy students from the University of Kansas and Creighton University.
NOTES
NOTES
John
Mill
ard,
Pha
rm.D
., BC
PS, B
CG
PA
SCP-
KS
Cha
pter
Spr
ing
Seni
or S
umm
itA
pril
14, 2
018
Pres
ente
r has
no
actu
al c
onfli
cts
of in
tere
st in
rela
tion
to th
is a
ctiv
ityM
ay h
ave
pote
ntia
l con
flict
s of
inte
rest
in re
latio
n to
the
follo
win
g:In
vest
ed in
to th
e TS
P fu
nds
with
no
cont
rol o
ver i
ndiv
idua
l ass
ets
allo
catio
n an
d as
a re
sult
may
dir
ectly
ow
n po
rtio
ns o
f the
co
mpa
nies
whi
ch p
rodu
cts a
re h
erew
ith in
dis
cuss
edC
o-fo
unde
d bi
otec
hnol
ogy
com
pany
Rec
alci
tran
t Sci
ence
LLC
Are
a of
rese
arch
: neu
rolo
gica
l and
men
inge
al in
fect
ious
dia
gnos
tic
mod
aliti
es
Dis
clos
ure
The
view
s ex
pres
sed
in th
is p
rese
ntat
ion
refle
ct th
ose
of th
e pr
esen
ter,
and
not n
eces
sari
ly th
ose
of th
e D
epar
tmen
t of V
eter
an A
ffair
s
Dis
clai
mer
o o o o o o
oo
o o o o o
o o o o o o
o o o
o o o
Stew
ard
ship
Bal
ance
Nee
d fo
r tim
ely,
ap
prop
riate
antim
icro
bial
initi
atio
n in
se
rious
infe
ctio
ns
Nee
d to
avo
id
unne
cess
ary
antim
icro
bial
use
to
prev
ent r
esist
ance
and
ad
vers
e ef
fect
s
Ove
rvie
w –
Nur
sing
Hom
e D
ata
o4.
1 m
illion
pat
ient
s are
ad
mitt
ed to
or r
esid
e in
nur
sing
hom
es
annu
ally
oUp
to 7
0% o
f nur
sing
hom
e re
siden
ts re
ceiv
e an
tibio
tics a
nnua
lly
oUp
to 7
5% o
f ant
ibio
tics a
re p
resc
ribed
inco
rrect
ly
o50
% o
f nur
sing
hom
e re
siden
ts re
ceiv
e in
appr
opria
te a
ntib
iotic
d
urat
ion
Hec
kerM
T, e
t al.
Arc
h In
tern
Med
. 20
03; 1
63:9
72-9
78
Con
sequ
ence
s of A
ntib
iotic
M
isus
e
Adv
erse
Dru
g Ev
ents
and
To
xici
ty
C. d
iffic
ile
Infe
ctio
n
Ant
ibio
tic
Resi
stan
t Pa
thog
ens
Exce
ss M
orta
lity
and
Cos
ts
Inap
prop
riat
e A
ntib
iotic
Use
Clin
Infe
ct D
is
Patie
nt C
ase
176
yea
r old
pat
ient
rece
ntly
dis
char
ged
with
Bac
tere
mia
2/2
ESB
L K
. pne
umon
iae.
C
urre
nt tr
eatm
ent E
rtap
enem
500
mg
IV q
pm–
adm
itted
for f
amily
con
cern
of f
ailu
re
to th
rive
pos
t dis
char
ge
Day
4 o
f rea
dmis
sion
: spi
ke in
whi
te c
ount
, afe
brile
, no
qSO
FA o
r SIR
S cr
iteri
a
Any
que
stio
ns fo
r the
nur
se o
r pat
ient
?
C. D
iff p
ositi
ve
Mos
t Com
mon
Adv
erse
Eve
nts
Alle
rgic
reac
tions
(80%
)A
dver
se e
ffect
s (1
8%)
Dia
rrhe
a, h
eada
che,
diz
zine
ss
Uni
nten
tiona
l ove
rdos
e (1
%)
Mos
t Com
mon
Ant
ibio
tics
Penc
illin
s(3
7%)
Fluo
roqu
inol
ones
(14%
)C
epha
losp
orin
s(1
2%)
Trim
etho
prim
-sul
fam
etho
xazo
le (1
1%)
Ant
ibio
tic A
dver
se E
vent
s
Clin
Infe
ct D
is. 2
008
Sep
15;4
7(6)
:735
-43.
ht
tps:
//w
ww
.cdc
.gov
/dru
gres
ista
nce/
thre
at-r
epor
t-201
3/[A
cces
sed
2017
Sep
tem
ber 0
9]
Ant
ibio
tic e
xpos
ure
is th
e fo
r the
de
velo
pmen
t of C
DI
Clos
trid
ium
diff
icile
Infe
ctio
n (C
DI)
Uni
ted
Stat
es C
ente
rs fo
r Dis
ease
Con
trol
and
Pre
vent
ion.
Ant
ibio
tic R
esis
tanc
e Th
reat
s in
the
Uni
ted
Stat
es, 2
013.
URL
: ht
tp:/
/ww
w.c
dc.g
ov/d
rugr
esis
tanc
e/th
reat
-rep
ort-2
013/
[Acc
esse
d 20
17 S
epte
mbe
r 09]
Frid
kin
S, e
t al.
Mor
bidi
ty a
nd M
orta
lity
Wee
kly
Repo
rt.
Uni
ted
Stat
es C
ente
r for
Dis
ease
Con
trol
and
Pre
vent
ion.
201
4; 6
3(09
):194
-200
.
C. d
iffic
ile
It is
a m
icro
biol
ogic
al d
iagn
osis
:10
cfu/
mL
in 2
con
secu
tive
urin
e sp
ecim
ens
Asy
mpt
omat
ic c
linic
ally
Freq
uent
ly a
ssoc
iate
d w
ith p
yuri
a35
% in
wom
en, 7
0% in
dia
betic
wom
en, 5
0% in
pre
gnan
t wom
en
90%
of i
nstit
utio
naliz
ed e
lder
ly p
atie
nts
100%
in p
atie
nt w
ith in
dwel
ling
cath
eter
s
Asy
mpt
omat
ic b
acte
riur
ia
Con
tam
inat
ion
Asy
mpt
omat
ic b
acte
riur
ia
Indi
catio
n fo
r tre
atm
ent:
Preg
nant
wom
enIn
crea
sed
risk
pye
lone
phri
tis (2
–3
fold
)In
crea
sed
prem
atur
ity a
nd lo
w b
irth
wei
ght
Patie
nts u
nder
goin
g in
vasi
ve G
U p
roce
dure
sPa
tient
with
bac
teri
uria
hav
e a
risk
of b
acte
rem
ia =
60%
Rena
l tra
nspl
ant r
ecip
ient
s
Asy
mpt
omat
ic b
acte
riur
ia
"Inf
ectio
us D
isea
ses
Soci
ety
of A
mer
ica
Gui
delin
es fo
r the
Dia
gnos
is a
nd T
reat
men
t of A
sym
ptom
atic
Bac
teri
uria
in A
dults
“-S
ee m
ore
at: h
ttp:/
/ww
w.id
soci
ety.
org/
Org
an_S
yste
m/#
Gen
itour
inar
y. 2
005
Cys
titis
Dys
uria
, Hem
atur
ia, F
requ
ency
, and
supr
apub
ic p
ain
Pyel
onep
hriti
sC
osto
vert
ebra
l ang
le te
nder
ness
, fev
er, u
rgen
cy,
dysu
ria,
chi
lls, n
ause
a, a
nd v
omiti
ng
Clin
ical
Pre
sent
atio
n
Loeb
Cri
teri
a
Empi
ric
trea
tmen
t bas
ed o
n yo
ur lo
cal a
ntib
iogr
amIn
gen
eral
ens
ure
you
have
E. c
oli c
over
age
To c
ultu
re o
r not
to c
ultu
reU
rine
cul
ture
is n
ot re
com
men
ded
for m
anag
ing
acut
e un
com
plic
ated
cy
stiti
s or t
hose
with
out U
TI sy
mpt
oms
Uri
ne c
ultu
re in
dica
ted
for
acut
e py
elon
ephr
itis
and
any
type
of c
ompl
icat
ed U
TIs
Trea
tmen
t
Trea
tmen
t
Clin
Infe
ct D
is 2
010;
5:62
5-63
; Clin
Infe
ct D
is 2
011;
5:e1
03-2
0D
iPir
oJT
,Tal
bert
RL,Y
eeG
C,e
tal,
eds.
Phar
mac
othe
rapy
:APa
thop
hysi
olog
icA
ppro
ach,
10th
ed.N
ewYo
rk:M
cGra
w-H
ill,2
017
CEL
LULI
TIS
FAST
FAC
TS
Infe
ctio
n of
epi
derm
is, d
erm
is, a
nd
supe
rfic
ial f
asci
a
http
s://w
ww
.aad
.org
/pub
lic/d
iseas
es/r
ashe
s/ce
llulit
is
Cel
lulit
is is
cons
ider
ed a
ser
ious
dise
ase
beca
use
of th
e pr
open
sity
of th
e in
fect
ion
to s
prea
d th
roug
h ly
mph
atic
tiss
ue a
nd to
th
e bl
oods
trea
m
http
s://w
ww
.may
oclin
ic.o
rg/d
iseas
es-c
ondi
tions
/cel
lulit
is/sy
mpt
oms-
caus
es/s
yc-2
0370
762
CLI
NIC
AL
PRES
ENTA
TIO
N
SIG
NS/
SYM
PTO
MS
Mal
aise
, Fev
er, C
hills
Alte
red
Men
tal S
tatu
s, H
ypot
ensio
n
Eryt
hem
a an
d ed
ema
Lesio
ns
Are
a w
arm
to to
uch
Infla
mm
atio
n
LABO
RATO
RY
FIN
DIN
GS
Leuk
ocyt
osis
Bact
erem
ia
DIA
GN
OSI
SC
BC
Clin
ical
Jud
gmen
t
LOEB
CRI
TERI
A
Mild
Typi
cal
Moderate
Syst
emic
Sig
ns o
f in
fect
ion
Mul
tiple
site
s of
infe
ctio
nC
ompl
icat
ing
fact
ors
–ag
e,
com
orbi
ditie
s, im
mun
osup
pres
sion
Abs
cess
es in
are
as d
iffic
ult t
o dr
ain
Severe
Faile
d an
tibio
tic tr
eatm
ent,
Imm
unoc
ompr
omise
d, C
linic
al s
igns
of
deep
er in
fect
ion
Empi
ric
Trea
tmen
t A
lgor
ithm
Man
dell,
Dou
glas
, and
Ben
nett’
s P
rinci
ples
and
Pra
ctic
e of
Infe
ctio
us D
isea
ses.
Phi
lade
lphi
a: C
hurc
hill
Livi
ngst
one
Els
evie
r,20
10:8
73-6
.R
espi
rMed
201
5;10
9:11
05-1
3.M
ande
ll, D
ougl
as, a
nd B
enne
tt’s
Prin
cipl
es a
nd P
ract
ice
of In
fect
ious
Dis
ease
s. P
hila
delp
hia:
Chu
rchi
ll Li
ving
ston
e E
lsev
ier,
2010
:877
-83
Cen
ter f
or D
isea
se C
ontro
l. G
et S
mar
t: K
now
Whe
n A
ntib
iotic
s W
ork
in D
octo
r’s O
ffice
s. h
ttps:
//ww
w.c
dc.g
ov/g
etsm
art/c
omm
unity
/abo
ut/in
dex.
htm
l. A
cces
sed
3/20
18A
nn In
tern
Med
200
1; 1
34(6
):518
-20.
; Am
Fam
Phy
sici
an 2
013;
88(
5):3
38-4
0.A
ntib
iotic
s fo
r acu
te b
ronc
hitis
. Coc
hran
e D
atab
ase
of S
yste
mat
ic R
evie
ws
2017
; Iss
ue 6
. Art.
No.
: CD
0002
45. D
OI:
10.1
002/
1465
1858
.CD
0002
45.p
ub4
Ann
Inte
rn M
ed 2
001;
134
(6):5
18-2
0.; A
m F
am P
hysi
cian
201
3; 8
8(5)
:338
-40.
; Ann
Inte
rn M
ed. 2
001;
134
(6):5
21-9
.; N
Eng
lJ M
ed. 2
006;
355
(20)
:212
5-30
.
Long
er d
urat
ions
may
be
nece
ssar
y if
bact
erem
ia
pres
ent
Men
,fol
eyca
thet
er, o
bstru
ctio
n
Long
er d
urat
ions
may
be
nece
ssar
y if
bact
erem
ia
pres
ent
IV to
PO
Equ
ival
ent C
hart
75 y
/o w
hite
mal
e w
ith a
PM
H D
M, C
KD
sta
ge 4
-5, a
nd N
KD
A p
rese
nts t
o ER
w
ith in
crea
sed
wea
knes
s, su
prap
ubic
tend
erne
ss, a
nd m
ore
SOB
with
any
ac
tivity
ove
r las
t 48
hour
s. H
e ha
d br
achi
ocep
halic
AV
fist
ula
plac
ed la
st w
eek
LUE
He
uses
oxy
gen
2 L
NC
at n
ight
and
prn
dur
ing
the
day.
UA
: WBC
s TN
TC,
RBC
s TN
TC, L
E m
oder
ate,
Nitr
ite n
egat
ive
WBC
s 16
,000
Tmax
: 100
.9F
all o
ther
vita
ls W
NLs
CXR
: Sm
all l
eft a
nd tr
ace
righ
t ple
ural
effu
sion
s w
ith a
djac
ent a
tele
ctas
is,
impr
oved
from
pri
or e
xam
. No
supe
rim
pose
d fo
cal c
onso
lidat
ive
infil
trat
e
Patie
nt C
ase
2
Patie
nt s
tart
ed o
n C
eftr
iaxo
ne 1
gm IV
q24
h 2/
2 U
TID
ay 3
of a
ntib
iotic
s pa
tient
’s W
BCs s
pike
and
bec
omes
febr
ileU
rine
cul
ture
: Gra
m n
egat
ive
rods
Bloo
d cu
lture
s: N
GTD
Wor
kup
for a
ltern
ativ
e so
urce
s of
infe
ctio
n ne
gativ
e
Cul
ture
resu
lts a
re re
port
ed o
ut in
the
afte
rnoo
n on
Day
3
Patie
nt C
ase
2
A.
Esca
late
ther
apy
to C
efep
ime
to a
ppro
pria
te re
nal d
ose
for 7
day
sB.
Con
tinue
cur
rent
ther
apy
(Cef
tria
xone
1gm
IV q
24hr
) to
com
plet
e 7
days
C.
Adj
ust C
eftr
iaxo
ne to
1gm
IV q
12hr
for 7
day
sD
.C
hang
e to
Lev
oflo
xaci
n to
app
ropr
iate
rena
l dos
e fo
r 14
days
Thou
ghts
?
Intr
insi
c re
sist
ance
to c
omm
on a
ntib
iotic
s 2/
2 A
mpC
-lact
amas
esRe
sist
ance
mec
hani
sms:
Enzy
mat
ic, E
fflux
pum
p(s)
, Por
inan
d M
embr
ane
perm
eabi
lity
alte
rnat
ions
Re
gard
less
of s
usce
ptib
ilitie
s D
OC
: Cef
epim
e or
Car
bape
nem
s
Ente
roba
cter
70 y
/o p
atie
nt p
rese
nted
to E
D fo
r 4 d
ays o
f dys
pnea
, sub
ject
ive
feve
r, pr
oduc
tive
coug
h, a
nd n
oted
flu
expo
sure
Adm
issi
on:
Acu
te h
ypox
emic
resp
irat
ory
failu
re 2
/2 C
AP
vs C
OPD
ex
acer
batio
n, a
nd in
fluen
zaTm
ax10
1, W
BCs 1
2.9,
Ban
ds 2
6%, R
R 28
, HR
111
Influ
enza
A p
ositi
ve
Empi
ric
trea
tmen
t: C
eftr
iaxo
ne, A
zith
rom
ycin
, Ose
ltam
ivir
, M
ethy
lpre
dnis
olon
e
Agr
ee o
r dis
agre
e w
ith e
mpi
ric
trea
tmen
t?
“To
be, o
r not
to b
e, th
at is
the q
uest
ion:
”
Day
3 o
f the
rapy
WBC
s 12
.9
15.1
0 14
.7Ba
nds
26
22
no d
iff o
n da
y 3
S. p
neum
onia
e ur
inar
y an
tigen
–po
sitiv
e G
roup
1 S
putu
m c
ultu
re:
3+ G
ram
-pos
itive
coc
ci; 1
+ G
ram
-neg
ativ
e co
cci;
1+ G
ram
-neg
ativ
e ro
dsD
ay 4
of t
hera
pyPa
tient
clin
ical
ly im
prov
ed
Sput
um c
ultu
re S
. pne
umon
iae
2+H
ospi
tal o
n di
vers
ion
requ
est f
or d
isch
arge
s
Patie
nt C
ase
3
Team
dis
cuss
ion
on ro
unds
: a te
am m
embe
r wan
ts to
de-
esca
late
th
erap
y to
Pen
VK
and
dis
char
ge
Com
plet
ed 3
day
s of C
eftr
iaxo
ne/A
zith
rom
ycin
……
……
……
….A
gree
or D
isag
ree…
……
……
……
……
……
….
Atte
ndin
g el
ects
to w
ait f
or s
usce
ptib
ilitie
s
Patie
nt C
ase
3Pa
tient
Cas
e 3
Mic
robi
olog
y Te
stin
go
Gra
m S
tain
sD
eter
min
e if
a ba
cter
ia is
gra
m p
ositi
ve o
r gra
m n
egat
ive
oSe
nsiti
vity
Rep
ort
Cul
ture
s sho
uld
be ta
ken
prio
r to
initi
atin
g an
tibio
tic
ther
apy;
oth
erw
ise
the
path
ogen
may
not
be
iden
tifia
ble
Det
erm
ines
whi
ch a
ntib
iotic
s are
sens
itive
to th
e or
gani
sm in
que
stio
n (S
, I, R
)O
nly
use
antib
iotic
s th
at th
e or
gani
sm is
sen
sitiv
e to
N
ever
use
an
antib
iotic
that
com
es b
ack
as R
or I
oBr
eakp
oint
s pu
blis
hed
by C
LSI o
r FD
Ao
Cla
ssify
MIC
s in
to S
usce
ptib
le (S
), In
term
edia
te (I
), Re
sist
ant (
R)
VIT
EK
Mul
tiple
upd
ates
to C
LSI b
reak
poin
tsC
urre
nt: C
LSI M
100
2017
In 2
010
CLS
I upd
ated
bre
ak p
oint
s for
Ent
erob
acte
riac
iae
Revi
sion
in b
reak
poin
ts o
ccur
due
toBa
cter
ial p
opul
atio
n di
stri
butio
nsBe
tter u
nder
stan
ding
of p
harm
acol
ogic
det
erm
inan
tsBa
cter
ial r
esis
tanc
e m
echa
nism
sPo
or o
utco
mes
from
ESB
L in
fect
ions
Why
Are
MIC
s im
port
ant?
73 y
/o p
atie
nt w
ith E
SRD
on
HD
MW
F is
set
to d
isch
arge
from
Hos
pita
l fo
r rig
ht h
eel O
steo
mye
litis
Ba
selin
e la
bs:
ESR
> 10
0; C
RP 1
4.9
Base
line
imag
ing
New
cor
tical
irre
gula
rity
of t
he c
alca
neus
with
ove
rlyi
ng so
ft tis
sue
defe
ct
is h
ighl
y co
ncer
ning
for o
steo
mye
litis
. Pa
tient
not
a c
andi
date
for M
RIBo
ne b
iops
y cx
: P. M
irab
ilis
3+
Patie
nt C
ase
4
Patie
nt d
isch
arge
d on
Cef
azol
in 2
gm to
be
give
n af
ter H
D o
n di
alys
is d
ays
Patie
nt C
ase
4
Patie
nt re
adm
itted
6 d
ays l
ater
for s
igni
fican
t wea
knes
s, h
ypot
ensi
on,
righ
t hee
l ulc
er re
open
ed a
nd in
nee
d of
wou
nd c
losu
reO
n ad
mis
sion
ther
apy
was
cha
nged
to P
iper
acill
in/T
azob
acta
m?
Patie
nt C
ase
4C
LSI M
100-
S20
(201
0)
FR is
a 7
1 y/
o w
hite
mal
e
Tran
sfer
red
from
a K
S M
edic
al C
ente
r dur
ing
sum
mer
of 2
017,
with
CC
of
seve
re h
eada
che,
exp
losi
ve d
iarr
hea,
nig
ht sw
eats
, chi
lls, a
nd d
ysur
ia.
Vita
ls: T
max
101.
8F,
RR
31, H
R 86
, BP
86/5
3
Star
ted
on IV
Cip
ro a
nd IV
Fla
gyl ,
on
arri
val a
dded
Zos
yn w
ith in
stru
ctio
ns to
co
ntin
ue F
lagy
l
Mic
robi
olog
y O
utsi
de H
ospi
tal:
urin
e cx
E. c
oli >
100
,000
CFU
/mL,
Day
3M
icro
biol
ogy
Robe
rt J.
Dol
e: a
ll cu
lture
s neg
ativ
e
Patie
nt C
ase
5C
ultu
re R
epor
t
Dia
gnos
is: S
epsi
s 2/2
E. c
oli U
TI
QTc
: Adm
issi
on: 4
14 m
sec
Day
3: 4
62 m
sec,
Cip
ro st
oppe
dD
ay 4
: 496
mse
c
No
know
n dr
ug a
llerg
ies
All
sym
ptom
s re
solv
ed a
nd p
atie
nt n
ow re
ady
for d
isch
arge
Wha
t is y
our a
ntib
acte
rial
PO
reco
mm
enda
tion?
Patie
nt C
ase
5C
ultu
re R
epor
t
CLS
I Bre
akpo
int R
evis
ions
Out
side
Hos
pita
l Mic
robi
olog
y la
b M
ICs,
app
ear t
o be
out
date
d
70 y
/o p
atie
nt p
rese
nts
to th
e ED
afte
r a n
on-V
A E
D s
ent h
im h
ome
last
ni
ght f
or in
crea
sing
SO
A, i
ncre
ased
sput
um p
rodu
ctio
n, a
nd c
hang
e in
pu
rule
nce
to a
bro
wni
sh c
olor
Chr
onic
resp
irat
ory
failu
re o
n 3
L O
2 at
hom
eV
ery-
seve
re C
OPD
1-vi
ew C
XR: T
here
is a
smal
l pat
chy
dens
ity a
t the
righ
t bas
e w
hich
pr
obab
ly is
sub
-seg
men
tal a
tele
ctas
is a
lthou
gh it
cou
ld re
pres
ent p
atch
y pn
eum
onia
Adm
issi
on d
x: A
cute
on
chro
nic
hypo
xic
hype
rcap
nic
resp
irat
ory
failu
re
2/2
CO
PD e
xace
rbat
ion
Star
ted
on L
evaq
uin
and
adm
itted
to th
e IC
U (f
loor
on
dive
rsio
n)
Patie
nt C
ase
6
WBC
s 18.
4 15
.0
12.7
Band
emia
12%
xx
xx
LAC
2.0
Patie
nt c
linic
ally
impr
ovin
g an
d tr
ansf
erre
d to
the
floor
pri
or to
the
wee
kend
Satu
rday
Day
3 –
4 Sp
utum
cx
orde
red
but n
ot c
olle
cted
Bloo
d cx
: 2/2
gra
m p
ositi
ve c
occi
Leva
quin
ther
apy
cont
inue
d ba
sed
on c
ultu
re re
port
Patie
nt C
ase
6
Earl
y M
onda
y m
orni
ng d
ay 4
–5i
shRR
incr
ease
s to
31, B
P dr
ops
64/4
1, a
nd p
atie
nt b
ecom
es fe
brile
for t
he fi
rst
time
Tmax
103.
1W
BCs
18.4
15
.0
12.7
19
.22
view
CXR
obt
aine
d:
Air
spac
e op
aciti
es in
the
righ
t low
er lo
be, r
ight
mid
dle
lobe
, and
righ
t up
per l
obe
conc
erni
ng fo
r mul
tifoc
al p
neum
onia
Sput
um c
x ob
tain
ed –
resu
lted
show
ed M
RSA
Patie
nt d
iagn
osed
with
CA
P w
ith b
acte
rem
ia 2
/2 M
RSA
Bloo
d &
Spu
tum
cul
ture
s sus
cept
ibili
ties a
re id
entic
al
Patie
nt C
ase
6“T
he C
hart
”
UpT
oDat
e
MRS
A is
kno
wn
to d
evel
op re
sist
ance
to q
uino
lone
s
Why
sho
uldn
’t I u
se th
e U
p-To
-Dat
e C
OPD
cha
rt
Why
?
Clin
Infe
ct D
is 2
006;
42:7
78-8
4J
Ant
imic
rob
Che
mot
her2
012;
67:
1010
-101
5
http
://w
ww
.fda.
gov/
dow
nloa
ds/D
rugs
/Dru
gSaf
ety/
UCM
5005
91.p
df
>32
mill
ion
pres
crip
tion
s in
2014
!
Der
esin
skiS
. ACH
med
ia 2
016;
Vol
35,
issu
e 9
Fluo
roqu
inol
one
Adv
erse
Effe
cts
CN
S ef
fect
s:H
allu
cina
tions
, con
fusi
on, r
are
chan
ce o
f sei
zure
Q
Tcpr
olon
gatio
n, c
ardi
ac a
rrhy
thm
ias,
dea
thPe
riph
eral
neu
ropa
thy
Tend
on in
flam
mat
ion/
rupt
ure
C. d
iffic
ilePh
otos
ensi
tivity
/ Ph
otot
oxic
ity
Hep
atot
oxic
ity
CLS
I Bre
akpo
ints
CLS
I Bre
akpo
ints
Fast
and
Fur
ious
Fast
and
Fur
ious
Fast
and
Fur
ious
1.M
erop
enem
/Vab
orba
ctam
(Vab
omer
e) –
CRE
2.
Cef
tazi
dim
e/A
viba
ctam
(Avy
caz)
–C
RE
3.Fo
sfom
ycin
in p
roce
ss la
bel e
xpan
sion
to H
AP,
VA
P, sk
in in
fect
ions
, co
mpl
icat
ed in
tra-
abdo
min
al in
fect
ion
4.D
elaf
loxa
cin
5.Le
fam
ulin
–M
DR
CA
P pa
thog
ens
6.C
efid
eroc
ol(s
ider
opho
rece
phal
ospo
rin)
–M
DR
Pseu
dom
onas
/Aci
neto
bact
er7.
Plaz
omic
in–
CRE
8.
Om
adac
yclin
e9.
Icla
prim
-St
aphy
loco
ccus
“no
evi
denc
e of
nep
hrot
oxic
ity”
10.E
rava
cycl
ine
–no
vel f
luor
ocyc
line
antib
iotic
for M
DRs
Que
stio
nsht
tps:
//w
ww
.med
scap
e.co
m/s
lides
how
/ten
-new
-ant
ibio
tics-
6009
164?
nlid
=118
667_
745&
src=
WN
L_m
dpls
feat
_171
024_
msc
pedi
t_ph
ar&
uac=
1510
84C
X&sp
on=3
0&im
pID
=146
4174
&fa
f=1
NOTES
NOTES
GERI-JEOPARDY SCORE SHEET
CAN’T CRUSH
THIS
HOME BREW
ALPHABET
SOUP
LAB RATS
A BEAUTIFUL
MIND
WITCH’S
BREW
$100 $100 $100 $100 $100 $100
$200 $200 $200 $200 $200 $200
$300 $300 $300 $300 $300 $300
$400 $400 $400 $400 $400 $400
$500 $500 $500 $500 $500 $500
TOTAL GERI-JEOPARDY SCORE: ___________
GERI-JEOPARDY SCORE SHEET
DOUBLE GERI-JEOPARDY Hit me
with your best shot
Can’t Touch This
Medicare Short Term Memory
$200 $200 $200 $200
$400 $400 $400 $400
$600 $600 $600 $600
$800 $800 $800 $800
$1000 $1000 $1000 $1000
TOTAL GERI-JEOPARDY SCORE
TOTAL DOUBLE GERI-JEOPARDY SCORE TOTAL
FINAL GERI-JEOPARDY WAGER
FINAL SCORE FINAL GERI-JEOPARDY QUESTION:
HOW TO OBTAIN CONTINUING EDUCATION CREDIT
FOR ASCP-KS SPRING SENIOR SUMMIT
Your CE certificate is the next page in this booklet
It is currently pending KS BOP approval for 4 CE hours
To receive CE Credit you MUST submit your completed copy of the CE certificate to the Kansas State Board of Pharmacy within 30 days of completion of the event.
Both Missouri and Oklahoma have agreed to reciprocate the Kansas CE but you will need to contact their respective Boards of Pharmacy for further instructions.
Certificates may be hand-delivered or submitted by mail to: Kansas State Board of Pharmacy
800 SW Jackson, Suite 1414 Topeka, KS 66612
or
Emailed to [email protected]
or
Faxed to 785-296-8420
This Certificate of Continuing Pharmaceutical Education Is awarded to
Name:_______________________ Address:_____________________ Pharmacist License #:__________
For Attending:
ASCP-KS CHAPTER SPRING SENIOR SUMMIT 2018 ON
APRIL 14, 2018 SPONSORED BY
KS Chapter American Society of Consultant Pharmacists
Pending approval by the KANSAS STATE BOARD OF PHARMACY
KBOP Course No. 18-014 4 hours of CPE credit
Kansas Board of Pharmacy 800 SW Jackson, Suite 1414
Topeka, KS 66612
Thank You to Our Sponsors
Thank you to our sponsors for empowering pharmacists to promote healthy aging through the appropriate use of medications.